Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | PRKCG | P05129 | 1/20 | 0.53 |
| ▸ | PRKCB | P05771 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | PRKCH | P24723 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 8/20 | 0.51 |
| ▸ | CDK2 | P24941 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976400 | 0.84 | PRKD3 (0.58) | PRKD3PRKCGPRKCBLCKPRKCA | |
| Hydrochloric Acid SCHEMBL6972570 | 0.83 | PRKD3 (0.57) | PRKD3PRKCGPRKCBLCKPRKCA | |
| SCHEMBL6977468 | 0.79 | IGF1R (0.57) | PRKD3PRKCGPRKCBLCKPRKCA | |
| SCHEMBL5549011 | 0.78 | SMN1; SMN2 (0.61) | PRKD3PRKCGPRKCBLCKPRKCA | |
| SCHEMBL1116462 | 0.74 | IGF1R (0.79) | PRKD3PRKCGPRKCBLCKPRKCA | |
| SCHEMBL14088802 | 0.74 | IGF1R (0.62) | PRKD3PRKCGPRKCBLCKPRKCA | |
| SCHEMBL28160275 | 0.74 | IGF1R (0.62) | PRKD3PRKCGPRKCBLCKPRKCA | |
| SCHEMBL4470281 | 0.73 | IGF1R (0.61) | PRKD3PRKCGPRKCBLCKPRKCA | |
| SCHEMBL1131578 | 0.73 | CDK2 (0.68) | PRKD3PRKCGPRKCBLCKPRKCA | |
| SCHEMBL6980935 | 0.72 | IGF1R (0.60) | PRKD3PRKCGPRKCBLCKPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | FREYNE EDDY JEAN E (BE) | 2005-08-11 | — | — | US | claimed |
| EP-1442019-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037869-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | claimed |
| EP-1442019-B1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-7183288-B2 | Amide derivatives as glycogen synthase kinase 3-β inhibitors | FREYNE EDDY JEAN EDGARD | 2007-02-27 | — | — | US | disclosed |
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | FREYNE EDDY JEAN E (BE) | 2005-08-11 | — | — | US | disclosed |
| EP-1442019-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037869-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
| EP-0862560-B1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-6235746-B1 | AUTOIMMUNE DISEASES; ANTIPROLIFERATIVE AGENT | CELLTECH THERAPEUTICS, LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| US-5958935-A | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| EP-0862560-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997019065-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | GSK3B, GSK3A, PHKG1 | PRKD3 113/4885PRKCG 167/4885PRKCB 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.